ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1378

Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort

Ha-Seul Jeoung1, Kuan Liu1, Roberta Berard2, Wes Fidler3, Janet Pope4, Johannes Roth5, Carter Thorne6, Earl Silverman7 and Deborah Levy8, 1University of Toronto, Toronto, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3St. Joseph's Hospital, Thunder Bay, ON, Canada, 4University of Western Ontario, London, ON, Canada, 5University of Ottawa, Ottawa, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 8Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Mortality, Pediatric rheumatology, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill this knowledge gap by analyzing outcomes in a large province-wide cSLE clinical cohort linked to multiple administrative healthcare databases. Our objectives were to: 1) determine all-cause and cause-specific mortality rates, adverse renal event rates, cardiovascular event rates, and cancer event rates in cSLE; and 2) determine baseline characteristics associated with higher rates of transition between 3 different states: event-free (entry), adverse renal event, and death.

Methods: Clinical data were abstracted for cSLE patients (< 18 years at diagnosis) diagnosed between January 1990 and March 2011 and followed for ≥1 year after contacting all pediatric and adult rheumatologists and nephrologists practicing in Ontario. Data and Ontario Health Insurance Plan (OHIP) numbers were securely transferred to the Institute for Clinical and Evaluative Sciences (ICES). OHIP numbers were transformed into an encrypted ICES key number (IKN) used to link the cohort to multiple administrative datasets to determine the outcomes of interest. We examined descriptive summaries of major outcomes including death, adverse renal events (end-stage kidney disease [ESKD] requiring chronic dialysis and renal transplant), cardiovascular events (including angina, transient ischemic attack, endocarditis, myocardial infarction, pericarditis, stroke), and cancer. In addition, we modeled the disease progression with a multi-state Cox model to determine baseline demographic and clinical characteristics that were significantly associated with higher rates of transition from being event-free to experiencing an adverse renal event, from being event-free to experiencing death, and from experiencing an adverse renal event to experiencing death.

Results: There were 38 deaths in a cohort of 615 patients with the mean follow-up time of 14.4 person-years. The all-cause mortality rate was 3.36 per 1000 person-years. The rates for end-stage kidney disease (ESKD) requiring chronic dialysis and renal transplant were 3.87 and 2.43 per 1000 person-years, respectively. The rate for any type of cardiovascular event and cancer were 6.49 and 3.47 per 1000 person-years, respectively. The multi-state Cox model indicated that the Black ethnic group (HR, 3.58; 95% CI, 1.6-8.0) and the presence of renal involvement at baseline (HR, 2.19; 95% CI, 1.2-4.1) were significantly associated with higher rates of transition from event-free to adverse renal event. Additionally, the Black ethnic group (HR, 5.45; 95% CI, 1.6-18.8) was significantly associated with higher rates of transition from event-free to death. None of the variables were significantly associated with higher rates of transition from adverse renal event to death.

Conclusion: In this large Canadian multi-ethnic long-term cSLE cohort, ethnicity was associated with adverse outcomes including adverse renal events and death. Further analyses will help inform risk for adverse outcomes to improve clinical care for the highest risk patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: H. Jeoung, None; K. Liu, None; R. Berard, None; W. Fidler, None; J. Pope, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Eli Lilly, merk, Roche, Seattle Genetics, UCB, Actelion, Amgen, Bayer, Eicos Sciences, Emerald, Gilead, Janssen, Novartis, Pfizer, Sandoz, Sanofi, Boehringer Ingelheim; J. Roth, None; C. Thorne, AbbVie/Abbott, Amgen, Celgene, CaREBiodam, Centocor, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Medexus/Medac, Merck; E. Silverman, None; D. Levy, None.

To cite this abstract in AMA style:

Jeoung H, Liu K, Berard R, Fidler W, Pope J, Roth J, Thorne C, Silverman E, Levy D. Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/childhood-onset-systemic-lupus-erythematosus-long-term-outcomes-in-a-large-multi-ethnic-ontario-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/childhood-onset-systemic-lupus-erythematosus-long-term-outcomes-in-a-large-multi-ethnic-ontario-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology